Pfizer says it removed some conditions from its Metsera bid

WILMINGTON, Delaware (Reuters) -Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.

Pfizer will ask a Delaware judge at a hearing on Wednesday to prevent Metsera from ending their merger agreement in favor of Novo’s offer. Pfizer said it removed conditions on direct sales of stock and public statements by Metsera.

(Reporting by Tom Hals in Wilmington, Delaware; Editing by Chris Reese)